Stockreport

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

Vir Biotechnology, Inc.  (VIR) 
PDF Phase 2 SOLSTICE subgroup analysis data in chronic hepatitis delta selected for poster presentation, and to be highlighted during EASL poster tour24 Week post-treatment [Read more]